Recent News

Adding Zanubrutinib to Obinutuzumab in CLL

Early Use of Lenalidomide With Pneumococcal Vaccine for High-Risk CLL

Genetic Landscape of CLL With IGH Translocations

SOHO 2020: Link Between WNT3 and LEF1 Expression Levels and Survival in CLL?

SOHO 2020: Interim Analysis of Real-World Registry of Elderly Patients With CLL

Managing CLL in the Era of COVID-19: Guidance From Global Experts

SOHO 2020: Debulking Regimens Prior to Venetoclax Therapy for CLL

SOHO 2020: Chemotherapy-Free Combination Therapy for CLL Under Study in Phase III Trial

Bendamustine Plus Rituximab in Older Patients With CLL: Swedish Real-World Study

Chemoimmunotherapy Regimen Under Study in Younger Patients With CLL

Case Report of Breast Involvement in a Male Patient With CLL

High-Risk CLL: Hematopoietic Stem Cell Transplantation Followed by Immune Intervention

Study Shows Benefit of Novel Agents for CLL With 17p Deletion

CLL and COVID-19: Large Italian Survey on Changes in Management

Case Report Features Potential Link Between JAK2 Inhibition and CLL

CLL and COVID-19: Treatment Lessons Learned

CLL and COVID-19: Continuity of Care in Italian Tertiary Hospital

FDA Clearance Granted for Assay for Monitoring Minimal Residual Disease in CLL

Dual PI3Kδ/CK1ε Inhibition on CLL T Cells

Predictors of Outcome in Patients with CLL and COVID-19

Can Prognosis Assessments Accurately Predict Time to First Treatment in Early-Stage CLL?

CLL and COVID-19: When May Humoral Immunity Therapy Be Indicated?

Zanubrutinib for Resistant CLL and Small Lymphocytic Lymphoma

Two Decades of Data Confirm Poor Prognosis With Richter Transformation in CLL

EHA25 Virtual: Quality of Life With Duvelisib Versus Ofatumumab in CLL

EHA25 Virtual: Does Administration Sequence of Ibrutinib/Obinutuzumab in CLL Affect Toxicity?

Real-World Study Finds VHA Adopts Novel Agents in CLL Treatment

AACR II: Linking HPV Infection to Skin Cancer in Patients With CLL

EHA25 Virtual: First-Line Ibrutinib/Venetoclax Combination in CLL

EHA25 Virtual: Trial Update on Ibrutinib Plus Umbralisib in Resistant CLL

ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL

EHA25 Virtual: Long-Term Results With Acalabrutinib in Treatment-Naive CLL

ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL

EHA25 Virtual: VENICE-I Findings With Venetoclax in Resistant CLL

EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL

ASCO20: Does Early Discontinuation of Venetoclax Affect Outcomes in CLL?

ASCO20: Cirmtuzumab Plus Ibrutinib in Relapsed or Refractory CLL

ASCO20: Final Results From ASCEND Trial of Acalabrutinib in Resistant CLL

ASCO20: Intermittent Scheduling of PI3Kδ Inhibitor in CLL

Chemotherapy-Free Treatment of CLL: Acalabrutinib With or Without Obinutuzumab

Managing CLL During the COVID-19 Pandemic: An International Survey of Experts

Ofatumumab Treatment and Rare Viral Infection of the Brain : A Case Study in CLL

Brazilian Task Force Offers Strategies for Managing COVID-19 and Lymphoid Malignancies

CLL-Related Cognitive Function: Disease Biology or Treatment Effect?

COVID-19 and Untreated Patients With CLL: Case Reports Shed Light on Clinical Risks

Mitochondrial Respiration: A Prognostic Marker of Response to CLL Treatment?

First-Line Ibrutinib Treatment of CLL: 5-Year Follow-up Results